A Randomized, Double-blind, Placebo-controlled, Parallel-group, 12-week Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety, and Tolerability of SAR440340 and the Coadministration of SAR440340 and Dupilumab in Patients With Moderate-to-severe Asthma Who Are Not Well Controlled on Inhaled Corticosteroid (ICS) Plus Long-acting β2 Adrenergic Agonist (LABA) Therapy
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2019
At a glance
- Drugs Dupilumab (Primary) ; SAR 440340 (Primary)
- Indications Asthma
- Focus Proof of concept; Therapeutic Use
- Sponsors Sanofi
- 15 Oct 2018 Planned End Date changed from 12 Dec 2019 to 27 Aug 2019.
- 15 Oct 2018 Planned primary completion date changed from 1 Sep 2019 to 9 Apr 2019.
- 14 Jun 2018 Planned End Date changed from 1 Dec 2019 to 12 Dec 2019.